Dimensional Fund Advisors LP lessened its stake in Horizon Pharma PLC (NASDAQ:HZNP) by 9.9% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,119,677 shares of the biopharmaceutical company’s stock after selling 671,956 shares during the quarter. Dimensional Fund Advisors LP owned 3.71% of Horizon Pharma worth $86,899,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently bought and sold shares of the company. Trexquant Investment LP purchased a new position in shares of Horizon Pharma in the 1st quarter worth about $2,008,000. American Century Companies Inc. raised its position in shares of Horizon Pharma by 158.5% in the 1st quarter. American Century Companies Inc. now owns 706,775 shares of the biopharmaceutical company’s stock worth $10,036,000 after purchasing an additional 433,359 shares during the last quarter. Systematic Financial Management LP purchased a new position in shares of Horizon Pharma in the 1st quarter worth about $1,428,000. Federated Investors Inc. PA raised its position in shares of Horizon Pharma by 140.8% in the 1st quarter. Federated Investors Inc. PA now owns 639,867 shares of the biopharmaceutical company’s stock worth $9,086,000 after purchasing an additional 374,107 shares during the last quarter. Finally, Swiss National Bank raised its position in shares of Horizon Pharma by 2.9% in the 4th quarter. Swiss National Bank now owns 278,156 shares of the biopharmaceutical company’s stock worth $4,061,000 after purchasing an additional 7,800 shares during the last quarter. 85.17% of the stock is owned by hedge funds and other institutional investors.

In related news, EVP Brian K. Beeler sold 17,931 shares of Horizon Pharma stock in a transaction dated Friday, May 25th. The stock was sold at an average price of $16.11, for a total value of $288,868.41. Following the completion of the sale, the executive vice president now directly owns 110,524 shares in the company, valued at approximately $1,780,541.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Chairman Timothy P. Walbert sold 83,353 shares of Horizon Pharma stock in a transaction dated Friday, June 1st. The stock was sold at an average price of $16.17, for a total value of $1,347,818.01. The disclosure for this sale can be found here. Insiders sold a total of 116,717 shares of company stock valued at $1,907,999 over the last quarter. 3.90% of the stock is owned by corporate insiders.

Several equities analysts have recently issued reports on HZNP shares. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $17.00 price target on shares of Horizon Pharma in a research report on Wednesday, March 14th. BidaskClub lowered Horizon Pharma from a “hold” rating to a “sell” rating in a research report on Thursday, March 22nd. Mizuho reaffirmed a “buy” rating and issued a $18.00 price target on shares of Horizon Pharma in a research report on Monday, May 7th. ValuEngine raised Horizon Pharma from a “sell” rating to a “hold” rating in a research report on Tuesday, May 8th. Finally, Morgan Stanley lifted their price target on Horizon Pharma from $14.00 to $16.00 and gave the stock an “equal weight” rating in a research report on Friday, March 2nd. Three equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. Horizon Pharma currently has a consensus rating of “Buy” and a consensus target price of $19.20.

Horizon Pharma opened at $17.43 on Wednesday, according to Marketbeat Ratings. Horizon Pharma PLC has a one year low of $10.10 and a one year high of $18.11. The stock has a market capitalization of $2.96 billion, a P/E ratio of 14.77, a price-to-earnings-growth ratio of 1.06 and a beta of 1.36. The company has a quick ratio of 1.50, a current ratio of 1.56 and a debt-to-equity ratio of 2.17.

Horizon Pharma (NASDAQ:HZNP) last released its quarterly earnings data on Wednesday, May 9th. The biopharmaceutical company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.11 by ($0.08). Horizon Pharma had a positive return on equity of 16.97% and a negative net margin of 45.06%. The business had revenue of $223.88 million during the quarter, compared to the consensus estimate of $232.05 million. During the same quarter in the previous year, the business posted $0.21 earnings per share. Horizon Pharma’s quarterly revenue was up 1.4% compared to the same quarter last year. sell-side analysts expect that Horizon Pharma PLC will post 1.43 EPS for the current year.

Horizon Pharma Profile

Horizon Pharma Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. The company's marketed medicine portfolio consists of RAVICTI for the treatment of urea cycle disorders; PROCYSBI to treat nephropathic cystinosis; ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; BUPHENYL to treat urea cycle disorders; and QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients.

Want to see what other hedge funds are holding HZNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Horizon Pharma PLC (NASDAQ:HZNP).

Institutional Ownership by Quarter for Horizon Pharma (NASDAQ:HZNP)

Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.